Proteasome inhibitors: Induction of apoptosis as new therapeutic option in prostate cancer;Proteasomeninhibitoren: Apoptoseinduktion als neue Therapieoption beim Prostatakarzinom?

Aktuelle Urologie

Volumn 35, Issue 6, 2004, Pages 491-496

  Tahmatzopoulos, A ^a,b   Gudegast, C ^a   Stockle M ^a   Wullich, B ^a   Unteregger, G ^b   Zwergel, U ^a   Zwergel, T ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Apoptosis drug effects physiology; Boronic acids pharmacology; Clinical study on humans; Multienzyme complexes antagonists and inhibitors; Prostate cancer drug therapy; Protease inhibitors pharmacology

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CELL PROTEIN; PROTEASOME; PROTEASOME INHIBITOR;

APOPTOSIS; CANCER CELL; CANCER THERAPY; CELL TYPE; HUMAN; NONHUMAN; PROSTATE CANCER; REVIEW; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8744280245     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830048     Document Type: Review

References (62)

1. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622
2. Adams J. Development of the proteasome inhibitor PS-341. The Oncologist 2002; 7: 9-16
3. Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002; 16: 433-443
4. Almond JB, Snowden RT, Hunter A, Dinsdale D, Cain K, Cohen GM. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukemia 2001; 15: 1388-1397
5. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998; 5: 1062-1075
6. An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 2003; 9: 4537-4545
7. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6910-6924
8. Baumeister W, Walz J, Zuhl F, Seemuller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998; 92: 367-380
9. Breckenridge DG, Germain M, Mathai JP, Nguyen M, Shore GC Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 2003; 22: 8608-8618
10. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79: 13-21
11. Cusack Jr JC, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin Jr AS. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61: 3535-3540
12. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 2004; 22: 115-119
13. Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000; 14: 65-77
14. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 1997; 94: 855-860
15. Drexler HC. Programmed cell death and the proteasome. Apoptosis 1998; 3: 1-7
16. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6: 3719-3728
17. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003; 22: 9030-9040
18. Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature 1991; 349: 132-138
19. Goodin S, Rao KV, DiPaola RS. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 2002; 7: 360-370
20. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA. Proteasomes play an essential role in thymocyte apoptosis. EMBO J 1996; 15: 3835-3844
21. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911
22. Gulley J, Dahut W. Novel clinical trials in androgen-independent prostate cancer. Clin Prostate Cancer 2002; 1: 51-57
23. Herrmann JL, Briones F, Brisbay S, Logothetis CJ, McDonnell TJ. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional bcl-2 and p53. Oncogene 1998; 17: 2889-2899
24. http://www.clinicaltrials.gov/ct/show/NCT00059631?order=2
25. http://www.clinicaltrials.gov/ct/show/NCT000646107order=1
26. Ikezoe T, Yang Y, Saito T, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci 2004; 95: 266-270
27. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin. 2004; 54: 8-29
28. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003; 22: 4953-4963
29. Kang Z, Pirskanen A, Janne OA, Palvimo JJ. Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 2002; 277: 48 366-48 371
30. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003; 100: 9946-9951
31. Leppa S, Bohmann D. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 1999; 18: 6158-6162
32. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A 2000; 97: 3850-3855
33. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL, Chang C. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 2002; 277: 36570-36576
34. Liu CY, Kaufman RJ. The unfolded protein response. J Cell Sci 2003; 116: 1861-1862
35. Logothetis CJ, Yang H, Daliani D. Dose dependent inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients (PTS) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341. Proc Am Soc Clin Oncol 2001; 20: 186a
36. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997; 272: 12893-12896
37. MacLaren AP, Chapman RS, Wyllie AH, Watson CJ. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001; 8: 210-218
38. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 1996; 56: 2649-2654
39. Masdehors P, Merle-Beral H, Magdelenat H, Delic J. Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk Lymphoma 2000; 38: 499-504
40. Masdehors P, Omura S, Merle-Beral H, Mentz F, Cosset JM, Dumont J, Magdelenet H, Delic J. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999; 105: 752-757
41. Meriin AB, Gabai VL, Yaglom J, Shifrin VI, Sherman MY. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J Biol Chem 1998; 273: 6373-6379
42. Naujokat C, Hoffmann S. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 2002; 82: 965-980
43. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002; 1: 1243-1253
44. Oefelein MG, Agarwal PK, Resnick MI. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 2004; 171: 1525-1528
45. Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 1999; 6: 303-313
46. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-685
47. Paillard F. Induction of apoptosis with I-kappaB, the inhibitor of NF-kappaB. Hum Gene Ther 1999; 10: 1-3
48. Pirtskhalaishvili G, Hrebinko RL, Nelson JB. The treatment of prostate cancer: an overview of current options. Cancer Pract 2001; 9: 295-306
49. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999; 162: 293-306
50. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18: 6938-6947
51. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617
52. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78: 761-771
53. Russo SM, Tepper JE, Baldwin Jr AS, Liu R, Adams J, Elliott P, Cusack Jr JC. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50: 183-193
54. Sadoul R, Fernandez PA, Quiquerez AL, Martinou I, Maki M, Schroter M, Becherer JD, Irmler M, Tschopp J, Martinou JC. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J 1996; 15: 3845-3852
55. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Waes C van. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419-1428
56. Tanaka K, Chiba T. The proteasome: a protein-destroying machine. Genes Cells 1998; 3: 499-510
57. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994; 13: 5433-5441
58. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003; 2: 835-843
59. Williams SA, McConkey DJ. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 2003; 63: 7338-7344
60. Wojcik C. Regulation of apoptosis by the ubiquitin and proteasome pathway. J Cell Mol Med 2002; 6: 25-48
61. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004; 23: 2009-2015
62. Zwergel T, Tahmatzopoulos A, Wullich B, Zwergel U, Stockle M, Unteregger G. Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures. Prostate Cancer Prostatic Dis 2004; 7: 138-143